The U. S. Food and Drug Administration (FDA) has decided to stop clinical trials that involve sending biological materials from Americans to "hostile countries" until they can confirm informed consent from those individuals. This decision comes amid security concerns regarding the handling of sensitive biological data.
• On June 18, 2024, the FDA announced a pause on trials exporting American cells due to security concerns and lack of informed consent.
• A new security rule, finalized in 2024, limits sensitive data exports to countries like China but previously allowed exceptions for biological samples.
• FDA officials, including Commissioner Dr. Marty Makary, expressed concerns that cells removed from Americans for treatment could be genetically altered abroad and then returned without proper testing or consent.
• Concerns include potential misuse of genetic data by foreign governments, particularly the Chinese Communist Party.
• The FDA is reviewing trials that relied on the exemption, requiring companies to demonstrate transparency and ensure ethical consent before trials can restart.
• NIH Director Dr. Jay Bhattacharya supported the halt, emphasizing the importance of protecting Americans' sensitive biological data while ensuring public trust in life-saving innovations.
• These measures align with executive orders previously signed by Presidents Biden and Trump aimed at restricting access to sensitive American personal data by foreign entities.
The FDA's suspension of trials reflects a significant step toward ensuring the security and consent of American participants in clinical research involving their biological materials. This halt is part of broader efforts to safeguard patient data in the context of national security.
No comments:
Post a Comment